IT8249719A0 - 2-/4-/(4,4-dialchil-2,6-piperidindi on-1-il)-butil/1-piperazinil/pirimi dine ad attivita' ansiolitica selettiva, procedimento per la loro preparazione e preparati farmaceutici che le contengono - Google Patents

2-/4-/(4,4-dialchil-2,6-piperidindi on-1-il)-butil/1-piperazinil/pirimi dine ad attivita' ansiolitica selettiva, procedimento per la loro preparazione e preparati farmaceutici che le contengono

Info

Publication number
IT8249719A0
IT8249719A0 IT8249719A IT4971982A IT8249719A0 IT 8249719 A0 IT8249719 A0 IT 8249719A0 IT 8249719 A IT8249719 A IT 8249719A IT 4971982 A IT4971982 A IT 4971982A IT 8249719 A0 IT8249719 A0 IT 8249719A0
Authority
IT
Italy
Prior art keywords
piperidindi
piperazinil
pirimi
dine
dialkyl
Prior art date
Application number
IT8249719A
Other languages
English (en)
Other versions
IT1158039B (it
Inventor
Davis L Temple
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of IT8249719A0 publication Critical patent/IT8249719A0/it
Application granted granted Critical
Publication of IT1158039B publication Critical patent/IT1158039B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IT49719/82A 1981-12-28 1982-12-22 2-/4-/(4,4-dialchil-2,6-piperidindion-1-il)-butil/1-piperazinil/pirimidine ad attivita' ansiolitica selettiva, procedimento per la loro preparazione e preparati farmaceutici che le contengono IT1158039B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/334,688 US4423049A (en) 1981-12-28 1981-12-28 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines

Publications (2)

Publication Number Publication Date
IT8249719A0 true IT8249719A0 (it) 1982-12-22
IT1158039B IT1158039B (it) 1987-02-18

Family

ID=23308351

Family Applications (1)

Application Number Title Priority Date Filing Date
IT49719/82A IT1158039B (it) 1981-12-28 1982-12-22 2-/4-/(4,4-dialchil-2,6-piperidindion-1-il)-butil/1-piperazinil/pirimidine ad attivita' ansiolitica selettiva, procedimento per la loro preparazione e preparati farmaceutici che le contengono

Country Status (26)

Country Link
US (1) US4423049A (it)
JP (2) JPS58118582A (it)
KR (1) KR870001045B1 (it)
AT (1) AT382373B (it)
AU (1) AU555797B2 (it)
BE (1) BE895504A (it)
CA (1) CA1244426A (it)
CH (1) CH656383A5 (it)
CY (1) CY1379A (it)
DE (1) DE3248160C2 (it)
DK (1) DK162389C (it)
ES (2) ES8405786A1 (it)
FI (1) FI70891C (it)
FR (1) FR2518993B1 (it)
GB (1) GB2114122B (it)
GR (1) GR77045B (it)
HK (1) HK5288A (it)
IE (1) IE54619B1 (it)
IT (1) IT1158039B (it)
KE (1) KE3709A (it)
LU (1) LU84561A1 (it)
NL (1) NL193283C (it)
PT (1) PT76036B (it)
SE (1) SE453088B (it)
SG (1) SG29787G (it)
ZA (1) ZA828549B (it)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4581357A (en) * 1983-02-07 1986-04-08 Mead Johnson & Company Antipsychotic 5-fluoro-pyrimidin-2-yl piperazine compound
DE3321969A1 (de) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US5187276A (en) * 1983-06-18 1993-02-16 Troponwerke Gmbh & Co. Kg. 2-pyrimidinyl-1-piperazine derivatives
CA1250291A (en) * 1984-07-23 1989-02-21 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)-piperazinyl derivatives of 1-pyrrolidin-2-ones
US4668687A (en) * 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
NL8601494A (nl) * 1985-06-22 1987-01-16 Sandoz Ag Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.
NZ216720A (en) * 1985-07-08 1990-09-26 Bristol Myers Co Diazinylpiperidine derivatives and pharmaceutical compositions
US4826843A (en) * 1985-07-08 1989-05-02 Bristol-Myers Cerebral function enhancing diazinylpiperidine derivatives
US4777254A (en) * 1986-12-02 1988-10-11 American Home Products Corp. Cyclic imides as H1 -antagonists
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US4782060A (en) * 1987-07-29 1988-11-01 Bristol-Myers Company Gepirone for alleviation of panic disorders
US4880930A (en) * 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
US5116970A (en) * 1988-02-18 1992-05-26 New James S Psychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones
US5001130A (en) * 1988-02-18 1991-03-19 Bristol-Myers Company Psychotropic heterobicycloalkylpiperazine derivatives
US4780466A (en) * 1988-03-17 1988-10-25 Hoechst-Roussel Pharmaceuticals, Inc. Arylpiperazinylalkoxy derivatives of cyclic imides
US5242911A (en) * 1988-06-17 1993-09-07 Pfizer Inc. Bridged bicyclic imides as anxiolytics and antidepressants
WO1990002552A1 (en) * 1988-09-16 1990-03-22 Pfizer Inc. Antipsychotic 4-[4-(3-benzisothiazolyl)-1-piperazinyl]butyl bridged bicyclic imides
FR2654934B1 (fr) * 1989-11-29 1994-09-30 Midy Spa Utilisation de derive [4-(2-pyrimidinyl)-1-piperazinyl] butyliques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale.
US5098904A (en) * 1990-06-27 1992-03-24 Bristol-Myers Squibb Company Cerebral function enhancing pyrimidinyl derivatives
AU9164591A (en) * 1990-12-14 1992-07-08 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DE4135551A1 (de) * 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
GB9223153D0 (en) * 1992-11-05 1992-12-16 Wyeth John & Brother Ltd Piperazine derivatives
FR2701260B1 (fr) * 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
US5338738A (en) * 1993-04-19 1994-08-16 Bristol-Myers Squibb Company Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .
US5538985A (en) * 1994-01-27 1996-07-23 Mitsui Toatsu Chemicals, Inc. Pyrrolidinone derivatives
CA2146593A1 (en) * 1994-05-05 1995-11-06 Jack Melton Large-scale process for azapirone synthesis
US5521313A (en) * 1994-05-05 1996-05-28 Bristol-Myers Squibb Company Process for preparing certain azapirones
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
WO2000006163A1 (en) * 1998-07-30 2000-02-10 Bristol-Myers Squibb Company Improved method for treatment of sleep-related respiratory disorders
US6566361B2 (en) 1999-06-30 2003-05-20 Laboratories, Upsa Azapirone pain treatment
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
CN100367965C (zh) * 1999-12-20 2008-02-13 法布瑞－克雷默制药有限公司 吉吡隆代谢物在制备改善哺乳动物不良心理状态的组合物上的应用
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
AU2001295478A1 (en) * 2000-08-22 2002-03-04 Akzo Nobel N.V. Active metabolite of gepirone
JP2004517081A (ja) * 2000-11-29 2004-06-10 イーライ・リリー・アンド・カンパニー １−（２−ｍ−メタンスルホンアミドフェニルエチル）−４−（ｍ−トリフルオロメチルフェニル）ピペラジンならびにその医薬的に許容しうる塩および溶媒和物
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
PT1651620E (pt) * 2003-07-30 2012-02-10 Xenon Pharmaceuticals Inc Derivados de piperizina e sua utilização como agentes terapêuticos
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
US20060099267A1 (en) * 2004-11-05 2006-05-11 Fabre-Kramer Pharmaceuticals, Inc. High-dosage extended-release formulation of gepirone
AU2004324868B2 (en) * 2004-11-05 2010-04-29 Fabre Kramer Holdings Inc High-dosage extended-release formulation of gepirone
HUE031039T2 (en) * 2007-03-29 2017-06-28 Joint-Stock Company Obninsk Chemical Pharmaceutical Company An antihistamine and an anti-allergenic agent and a method for its preparation
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
IT201900000657A1 (it) 2019-01-16 2020-07-16 Procos Spa Processo per la sintesi di gepirone
GB202014736D0 (en) * 2020-09-18 2020-11-04 Imperial College Innovations Ltd Novel compounds and their use in therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3398151A (en) * 1966-02-01 1968-08-20 Mead Johnson & Co Azaspirodecanediones and azaspiroundecanediones
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
FI791926A (fi) 1978-06-20 1979-12-21 Synthelabo Fenylpiperazinderivat
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines

Also Published As

Publication number Publication date
ES518510A0 (es) 1984-06-16
GR77045B (it) 1984-09-04
FI70891B (fi) 1986-07-18
AT382373B (de) 1987-02-25
IT1158039B (it) 1987-02-18
DK162389C (da) 1992-03-09
US4423049A (en) 1983-12-27
FR2518993A1 (fr) 1983-07-01
ZA828549B (en) 1983-09-28
SG29787G (en) 1987-07-17
NL193283B (nl) 1999-01-04
JPH06293753A (ja) 1994-10-21
HK5288A (en) 1988-01-29
GB2114122A (en) 1983-08-17
DK162389B (da) 1991-10-21
KR870001045B1 (ko) 1987-05-26
SE453088B (sv) 1988-01-11
CA1244426A (en) 1988-11-08
CY1379A (en) 1987-08-07
ATA469882A (de) 1986-07-15
KE3709A (en) 1987-04-16
FI824442A0 (fi) 1982-12-23
AU9108382A (en) 1983-07-07
IE823067L (en) 1983-06-28
KR840002827A (ko) 1984-07-21
DE3248160C2 (de) 1993-12-09
FR2518993B1 (fr) 1986-09-05
LU84561A1 (fr) 1983-09-08
JPS58118582A (ja) 1983-07-14
FI70891C (fi) 1986-10-27
IE54619B1 (en) 1989-12-20
CH656383A5 (de) 1986-06-30
DE3248160A1 (de) 1983-07-07
BE895504A (fr) 1983-06-28
DK573182A (da) 1983-06-29
NL193283C (nl) 1999-05-06
SE8207425L (sv) 1983-08-12
FI824442L (fi) 1983-06-29
SE8207425D0 (sv) 1982-12-27
AU555797B2 (en) 1986-10-09
NL8204970A (nl) 1983-07-18
GB2114122B (en) 1985-11-27
JPH0368875B2 (it) 1991-10-30
ES8506696A1 (es) 1985-08-01
PT76036B (en) 1985-12-16
ES524945A0 (es) 1985-08-01
PT76036A (en) 1983-01-01
ES8405786A1 (es) 1984-06-16

Similar Documents

Publication Publication Date Title
IT8249719A0 (it) 2-/4-/(4,4-dialchil-2,6-piperidindi on-1-il)-butil/1-piperazinil/pirimi dine ad attivita' ansiolitica selettiva, procedimento per la loro preparazione e preparati farmaceutici che le contengono
IT8467767A1 (it) Preparati farmaceutici ad attività antimicrobica e procedimento per la loro preparazione.
IT1213379B (it) Tiazolo [4,5-c]chinoline, procedimento per la loro preparazione e composizioni farmaceutiche che le contengono.
IT8622482A0 (it) Spray di diidropiridina, procedimento per la sua produzione e suo impiego farmaceutico.
DE3261497D1 (en) Substituted n-(4-indolyl-piperidino-alkyl) benzimidazolones, processes for their preparation and their use as pharmaceutical preparations
IT8249720A0 (it) 2-/4-/4,4-dialchil-2,6-piperidinadion-1-il)butil/-1-piperazinil/piri dine ad attivita' antipsicotica relativo procedimento di preparazione e preparati farmaceutici che le con tengono
IT8667183A0 (it) Derivati di anilina terapeuticamente attivi,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
IT8324035A0 (it) Cefem composti ad attivita'farmaceutica e procedimenti per laloro preparazione.
DK165635C (da) 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-1,8-naphthyridin-3-carboxy-derivater, farmaceutisk praeparat omfattende saadanne forbindelser, samt fremgangsmaade til fremstilling af forbindelserne
DK159652C (da) Cholecalciferolderivater, disse derivater til brug som terapeutisk aktive substanser, fremgangsmaade til fremstilling deraf samt farmaceutisk praeparat baseret paa disse cholecalciferolderivater
DK354485A (da) 3-substituerede l-aminoalkyl-lh-indol-forbindelser, fremgangsmaader til fremstilling deraf og mellemprodukter til anvendelse derved samt farmaceutiske praeparater
IT8249771A0 (it) Derivati di cicloesanone aventi attivita' diserbante, e procedimento per la loro preparazione
IT1168389B (it) Derivati di alcandioli con attivita' ipolipidemizzante,metodi per la loro preparazione e composizioni farmaceutiche che li contengono
IT1168163B (it) Composto ad attivita' antiulcera, procedimento per la sua preparazione e composizioni farmaceutiche relative
IT8322045A0 (it) Per la loro preparazione e oligosaccaridi eterogenei relative composizioni complessabili ed alfa -idosani ad farmaceutiche. attivita' terapeutica, procedimento
IT8121298A0 (it) Nitroimidazoli ad attivita'tricomonacida, procedimento per laloro preparazione e relative composizioni farmaceutiche.
IT1185513B (it) Procedimento per l'ottenimento di preparati farmaceutici con effetto ritardato
IT8567216A0 (it) Composti pteridinici relativi procedimenti di preparazione e preparati farmaceutici che li contengono
IT8026232A0 (it) Composizioni farmaceutiche. derivato dell'alfa-mercapto propionilglicina ad attivita'terapeutica, procedimento per lasua preparazione e relative
IT8421431A1 (it) "nuovi preparati farmaceutici con azione antitumorale"
IT8321223A0 (it) Composizione farmaceutica acarattere di collirio ad azione antiinfiammatoria, e procedimento per la sua preparazione.
IT8520150A0 (it) Nuovi derivati ad attivita'terapeutica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
IT1194572B (it) Preparati farmaceutici tipici ad attivita' antisettica ed antiinfiammatoria spinta,e procedimento per la loro preparazione
IT8222339A0 (it) Composti ad attivita'calcio-antagonista, metodo per laloro preparazione e composizioni farmaceutiche.
IT8222494A0 (it) Derivati ad attivita'espettorante, procedimento per laloro preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19961227